COX-2 selective inhibitors and heart health

被引：0
|
作者：
Simon, Lee S. [3 ,4 ]
White, William B. [1 ,2 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Clin Trials Unit, Farmington, CT 06030 USA
[2] Univ Connecticut, Sch Med, Calhoun Cardiol Ctr, Farmington, CT 06030 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
POSTGRADUATE MEDICINE | 2005年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
On September 30, 2004, because of an observed increased risk of serious cardiovascular (CV) events, Merck & Co, Inc, voluntarily withdrew rofecoxib from the worldwide market. The withdrawal has focused attention on the possible class effect on the cardiovascular system of the other currently available cyclooxygenase-2 (COX-2) selective inhibitors: celecoxib and valdecoxib. This review evaluates and differentiates the CV effects of COX-2 selective inhibitors through an assessment of prospective, randomized epidemiologic studies and meta-analyses.
引用
收藏
页码：7 / 20
页数：14
相关论文
共 50 条
  • [41] Cyclooxygenase-2 (COX-2) in carcinogenesis and selective cox-2 inhibitors for chemoprevention in gastrointestinal cancers
    Fujimura T.
    Ohta T.
    Oyama K.
    Miyashita T.
    Miwa K.
    Journal of Gastrointestinal Cancer, 2007, 38 (2-4) : 78 - 82
  • [42] COX-2 selective inhibitors - important lessons learned
    Maxwell, SRJ
    Webb, DJ
    LANCET, 2005, 365 (9458): : 449 - 451
  • [43] Selective COX-2 inhibitors: is the water becoming muddy?
    Wallace, JL
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (01) : 4 - 6
  • [44] Clinical pharmacology of novel selective COX-2 inhibitors
    Tacconelli, S
    Capone, ML
    Patrignani, P
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (06) : 589 - 601
  • [45] Aspirin, selective COX-2 inhibitors and gastrotolerance - Foreword
    Fiorucci, S
    Morelli, A
    Porro, GB
    DIGESTIVE AND LIVER DISEASE, 2001, 33 : S1 - S1
  • [46] Selective COX-2 inhibitors vs NSAIDs discussed
    Reactions Weekly, 2002, 906 (1) : 3 - 3
  • [47] No increase in acute MI with selective COX-2 inhibitors
    Reactions Weekly, 2003, 947-948 (1) : 5 - 5
  • [48] The future of NSAID therapy: selective COX-2 inhibitors
    Vane, JR
    Botting, RM
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2000, 54 (01) : 7 - 9
  • [49] Risk of hyperkalemia associated with selective COX-2 inhibitors
    Aljadhey, Hisham
    Tu, Wanzhu
    Hansen, Richard A.
    Blalock, Susan
    Brater, Craig
    Murray, Michael D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (11) : 1194 - 1198
  • [50] NSAID COX-2 selective inhibitors: hopes and incertitudes
    Bannwarth, B
    PRESSE MEDICALE, 1999, 28 (22): : 1180 - 1181
12345